SUBSCRIBE
SUBSCRIBE
News   FDA

GlaxoSmithKline Obtains Additional Approval For Anti-Influenza Drug RELENZA In Japan

February 20, 2006 | 
1 min read
Tokyo, Feb 20, 2006 (JCN) - GlaxoSmithKline (GSK) has obtained approval for additional indication for RELENZA (zanamivir), its proprietary agent for treating influenza A and B virus infections, from the Ministry of Health, Labor and Welfare.
FDA Approvals Asia
GlaxoSmithKline
MORE ON THIS TOPIC
Adult hand intends to puncture a balloon held by a girl. Child neglect and suppression dreams and wishes of kid. Parental control and authoritarian nurturing. Psychological abuse and domestic violence
Antibody-drug conjugate
GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma
July 16, 2025
 · 
2 min read
 · 
Tristan Manalac
COVID-19
Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
July 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
 · 
1 min read
 · 
Heather McKenzie
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac